People are questioning as to what advantage PAD has over other...

People are questioning as to what advantage PAD has over other products. I would like to ask how TZ cannot sell a fully functioning replica product into a massively growing market. Surely this is a not so difficult thing to do now?

Where is/was the road block? Was it John Wilson's failed strategy of offering trials with the supreme confidence/expectation that the buyer would have to continue with the incumbent? Is it pricing? - With stubborn corporate overheads, TZ's inability to compete on price? Or is it just plain lack of ability?

Considering growing IXP and PDT revenues, TZ's share price could bounce so long as management cuts unnecessary costs dramatically - including their own pay - which, considering their track record at TZ over 3 years, IS unnecessarily high for TZ to flourish.